CKD AS A COMMUNITY DISEASE.
Sponsored by Roche
Chair:Paul
Stevens, Kent & Canterbury Hospital
Early detection and prevention: community based cornerstones of modern
CKD management.
Guest Speaker: Adeera Levin,
Professor of Medicine, University of British Columbia, Canada
O41 Chronic kidney disease in primary care
P K Mitra, St. James Medical Practice, Kings Lynn
CKD in primary care.
Guest Speaker: Ian Wilkinson, General Practitioner, Oldham
Primary Care Trust, Manchester
|
THE RENAL REGISTRY
Chair: John Feehally, Leicester General Hospital, President,
The Renal Association
The Renal Association UK
Renal Registry - A Tool to help improve renal care.
Terry Feest,
Professor of Nephrology, Southmead Hospital, Bristol
O42 Does transplantation improve
survival for end stage renal disease patients in the UK?
C Dudley, UK Renal
Registry, Southmead Hospital, Bristol
O43
Elderly
patients on renal replacement therapy in the UK : UK Renal Registry
C Byrne, UK Renal Registry, Southmead
Hospital, Bristol
044
Does
1st year renal transplant function influence longer term haemoglobin, bone
metabolism and blood pressure ?
R Rao, The Renal Registry, Southmead Hospital, Bristol
|
CONSERVATIVE CARE FOR PAIENTS WITH
End STAGE RENAL FAILURE
Chair: Cathy Holman, York Hospital
O45
Interface of renal and palliative care services:
impact of action learning sets?
S Gomm, Hope Hospital, Salford
O46 Effective delivery of a conservative management
service for patients with stage 5 CKD
JC Daniels, Kent & Canterbury
Hospital
O47 Dialysis
or not? A comparative survival study of elderly patients with end stage
renal disease
FEM Murtagh, King’s College London
O48 A review of patients receiving conservative care
for ESRF
M Higginbotham, York Hospital
O49 Factors
influencing the success of running a maximum conservative medical treatment
in patients approaching end stage CKD
CF Wong, Royal Liverpool University Hospital
|
LABORATORY SCIENCE:
PROGRESSION IN RENAL DISEASE.
Chair: Caroline
Savage, The Medical School, University of Birmingham
Cell Signalling and new
therapies in progressive renal disease.
Guest Speaker: Bruce
Hendry, Professor of Renal Medicine, King’s College Hospital, London
O50
Knockout of transglutaminase type 2 slows the development of kidney
scarring in the mouse UUO model
NB Mohammed, Sheffield Kidney
Institute
O51 Cyclin I protects
podocytes from apoptosis by stabilising p21Cip1/Waf1
SV Griffin, University of Washington Medical School,
Seattle, WA, USA
O52 Hic-5 Mediates extracellular matrix control of
mesangial cell apoptosis
JN Hornigold, St. James’s University Hospital, Leeds
|
PERITONEAL DIALYSIS FORUM
Co-Chair: Althea Mahon, St. Bartholomew’s and The
London Hospital & Nick Topley, Institute of Nephrology, University of
Wales College of Medicine
O53 CCL-18 and
Angiogenin: Novel cytokines present in PD fluid and involved in regulation
of inflammation and fibrosis in the peritoneal membrane
A Ahmad, Imperial College London
O54 CAPD with
hypertonic glucose containing solution induces hyperglycaemia and is
associated with an adverse haemodynamic response in non-diabetic PD
patients
NM Selby, Derby City Hospital
O55 Prediction and
consequences of plasma concentrations of Icodextrin (ICO) metabolites in
PD patients
SJ Davies, University Hosp. Of North Staffordshire
O56 A retrospective
review of peritoneal dialysis and the treatment of severe heart failure
E Green, York Hospital
O57 Clinical risk
factors for encapsulating peritoneal sclerosis and the value of abdominal
computed tomography as a screening tool
M Chanayireh, Manchester Royal Infirmary
|
